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Term and preterm newborns suffering from severe
hypoxaemic respiratory failure, either due to persistent
pulmonary hypertension (PPHN) or respiratory distress
syndrome (RDS), still account for a relatively high mor-
bidity and mortality [1, 2]. Several treatments have been
attempted in these patients, such as exogenous surfactant
replacement, i.v. vasodilators such as tolazoline and prosta-
cyclins, inhaled prostacyclins, magnesium sulphate, high-
frequency ventilation and liquid ventilation, although
rarely has their efficacy been confirmed by controlled stud-
ies [3–6]. Extracorporeal membrane oxygenation (ECMO)
constitutes a valid therapeutic option in neonates with
refractory hypoxaemia [7, 8], as recently confirmed by the
UK ECMO collaborative trial [9]. However, ECMO re-
mains a complex and expensive technique that requires
systemic anticoagulation and cannulation of major vessels.
Inhaled nitric oxide (NO) has been shown to be a promis-
ing novel treatment in hypoxaemic newborns with severe
PPHN, either idiopathic or secondary to various cardiopul-
monary diseases. In using this therapy several authors have
observed a marked improvement of oxygenation in most
patients and a decline of ECMO cases [10–12]. It is still
unclear, however, why in some patients gas exchange
during NO therapy is not improved and whether, in cases
of positive response, a rapid improvement of oxygenation
is necessarily associated with a favourable outcome. The
objectives of this study were: 1) to assess the acute phy-
siological effect of inhaled NO on systemic oxygenation
in newborns with acute respiratory failure approaching
ECMO criteria; and 2) to evaluate whether survival with-
out ECMO support was correlated to an acute and sustai-
ned response to inhaled NO and, conversely, whether death
or need for ECMO could be anticipated by a poor or absent
response.
Methods
This study was approved by the Ethics and Scientific
Review Board at the Department of Paediatrics, Univer-
sity of Padova. Informed parental consent was obtained
prior to initiation of NO therapy. All newborns admitted at
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ABSTRACT: The aim of this study was to evaluate the effect of inhaled nitric oxide
(NO) in newborns with acute hypoxaemic respiratory failure and the impact of this
NO therapy on survival and the need for extracorporeal membrane oxygenation
(ECMO).
A cohort of newborns with a gestational age of ≥34 weeks and an oxygenation in-
dex (OI) >25 were prospectively evaluated. Patients were given NO at an initial dose
of 10 parts per million (ppm). Oxygenation parameters were evaluated prior and dur-
ing NO inhalation. From January 1994 to December 1996, 20 infants were en-rolled
in the study. Based upon their outcome, patients were divided into two groups: survi-
vors with no need for ECMO, group A (n=8) and survivors requiring ECMO or non-
survivors, group B (n=12).
All infants approached or met ECMO criteria before NO inhalation. Eight pati-
ents (40%) were successfully managed with NO and conventional treatment (group
A). Newborns in this group showed a rapid and sustained improvement of systemic
oxygenation during NO inhalation. Mean arterial oxygen tension (Pa,O2) increased
significantly from 4.5 kPa (34 mmHg) (95% confidence interval (95% CI) 1.9–7.1
kPa (14.4–53.7 mmHg)) to 10.1 kPa (75.7 mmHg) (95% CI 6.5–13.6 kPa (49.1–102.3
mmHg)) after 1 h and was 9.0 kPa (67.7 mmHg) (95% CI 7.1–11.0 kPa (53.1–82.4
mmHg)) at 24 h. Conversely, none of the oxygenation parameters improved in the 12
patients who ultimately required ECMO or died (group B).
The results indicate that inhaled nitric oxide can improve systemic oxygenation in
newborns with acute respiratory failure and may reduce the need for extracorporeal
membrane oxygenation support in candidates. Lack of a rapid response to nitric
oxide may be an early predictor of unfavourable short-term outcome, prompting a
move towards alternative treatments.
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the Neonatal Intensive Care Unit (NICU) of the Institu-
tion were considered as possible candidates for this study.
Patients with congenital heart defects were excluded. In-
fants had to be mechanically ventilated, with an inspira-
tory oxygen fraction (FI,O2) of 1.0. Entry criterion was an
oxygenation index (OI) >25, despite optimization of con-
ventional support, i.e. haemodynamic support with inot-
ropes and/or fluids, alkalinization by hyperventilation or
buffer infusion, sedation and/or muscle relaxation and
one or more doses of exogenous surfactant (Curosurf®;
Chiesi, Parma, Italy). Vital parameters were continuously
monitored throughout the study period. For the 2-D echo-
cardiographic and Doppler studies, CFM 700 (Vingmed,
Horten, Norway) mechanical equipment was used. Echo-
cardiographic evaluations were performed before and dur-
ing the first hour of NO inhalation, in order to identify
signs of extrapulmonary right-to-left shunting at the duc-
tal and/or the foramen ovale level and to assess the effect
of NO on pulmonary vascular resistance.
NO delivery and monitoring
NO was provided in 20 L cylinders (Air Liquide Sanità,
Milan, Italy), at a certified concentration of 500–520
parts per million (ppm) of NO in nitrogen, with a nitrogen
dioxide (NO2) content <1%. During assisted ventilation,
performed either with a conventional time cycled, pres-
sure limited, continuous flow ventilator (Babylog 8000;
Sensor Medics, Dräger, Lübeck, Germany) or with a high-
frequency oscillatory ventilator (3100A; Yorba Linda,
CA, USA), the NO mixture was administered in the inspi-
ratory limb of the circuit by means of a low-scale flow
regulator, at about 40 cm from the Y-connector. We main-
tained a ventilator gas flow rate at ≥10 L·min-1, in order to
minimize the contact time between NO and oxygen within
the circuit, thus reducing the formation of higher nitro-
gen oxides. NO and NO2 concentrations were continuous-
ly monitored, either with a chemiluminescence analyser
(CLD 700 AL med; ECO Physics, Dürnten, Switzerland)
or by electrochemical sensors (Triple plus, Crowcon, UK;
Noxide M3 AIME, Dräger, Corsico-Milan, Italy). The gas
mixture was sampled from the inspiratory limb of a modi-
fied ventilator circuit, just before the endotracheal tube.
Exhaust gases were scavenged. Methaemoglobin (metHb)
levels were measured every 8–12 h in the early phase of
treatment, and then twice a day. NO concentration had to
be reduced or ultimately stopped in case of NO2 levels >2
ppm or metHb values persistently >5%.
Study protocol
Inhalation of NO was started at an initial concentration
of 10 ppm. When systemic oxygenation did not improve
after the first few minutes of NO inhalation, the caring
physician could increase the initial NO dose, by steps of
10 ppm up to a maximum of 40 ppm. Conversely, when
there was a marked improvement of oxygenation during
the first hours of NO inhalation, the FI,O2 and/or the peak
pressure of the ventilator could be lowered in order to
limit further damage to the lungs. The arterial oxygen
pressure (Pa,O2), OI and alveolar-arterial pressure diffe-
rence for oxygen (PA-a,O2) were evaluated immediately
prior to NO inhalation, and after 1, 3, 6, and 24 h of the-
rapy. OI and PA-a,O2 were calculated with the following
formulas:
OI = mean airway pressure × FI,O2 × 100/postductal Pa,O2
PA-a,O2 = (760-47) × FI,O2 - Pa,O2 - Pa,CO2
where 760 is the barometric pressure (mmHg); 47 is the
partial pressure of water vapour (mmHg); and Pa,CO2 is
the arterial carbon dioxide tension. Newborns with birth
weight >2,000 kg and gestational age ≥34 weeks, with OI
≥40 for >3 h and/or PA-a,O2 >610 mmHg for more than
8 h, were considered candidates for ECMO [8]. ECMO
was initiated in cases of values persistently beyond such
limits, despite NO inhalation. In the study centre veno-
venous or veno-arterial ECMO by means of a roller occlu-
sive pump (Jostra®, Hirrlingen, Germany) and two types
of silicone membrane oxygenator (Avecor®, Plymouth
MN, USA; Jostra®) were provided.
According to survival and the use of ECMO, patients
were divided into two groups: survivors not requiring
ECMO (group A) and survivors requiring ECMO treat-
ment or nonsurvivors (group B).
Statistical analysis
Demographic data, duration and doses of NO, and
metHb are expressed as median and range, while gas
exchange parameters are expressed as mean and 95%
confidence intervals (95% CI) unless specifically stated
otherwise.
Because data were not normally distributed, nonpara-
metric statistical analyses were used for within-group
(Wilcoxon Signed-Rank test) and between group (Mann-
Whitney U-test) comparisons. The rate of right-to-left
shunting reversal in the two groups was compared with
the Fisher exact test (two-tailed). A p-value <0.05 was
considered statistically significant. Data elaboration was
performed by using a specific software (Statistica, ©Stat-
Soft Inc., Tulsa, OK, USA).
Results
Between January 1994 and December 1996, 20 infants
with severe hypoxaemic respiratory failure were enrolled
in the study. Demographic and outcome data for all pa-
tients are shown in table 1. In the whole group, mean Pa,O2
before NO inhalation was 4.5 kPa (33.7 mmHg) (95% CI
3.2–5.7 kPa (24.2–43.1 mmHg)), PA-a,O2 was 83.0 kPa
(623 mmHg) (95% CI 81.3–84.5 kPa (611–635 mmHg))
and OI was 76.4 (95% CI 58.6–94.2). The duration of NO
inhalation was 33 h (range 6–331). Median initial and
maximal NO doses were 10 and 30 ppm, respectively. In a
few patients, due to their agonic conditions, the caring
physician started with higher NO concentrations (≤40
ppm). Two unresponsive patients received a short NO trial
at 80 ppm, with no benefit.
Eight patients survived without ECMO (group A),
while 10 were treated with ECMO and two died be-
fore ECMO (group B). Patient characteristics in the two
groups are shown in table 2. Except for the three infants
with RDS and the six with congenital diaphragmatic
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hernia (CDH) who belonged to group A and group B, res-
pectively, the other diagnoses were unevenly distributed in
the two groups. As far as the gestational age, birth weight,
 gender, inborn/outborn rate and Apgar scores were con-
cerned the two groups were comparable. Three patients,
all with CDH, were given a trial with high-frequency os-
cillatory ventilation (HFOV) prior to NO inhalation. All
six patients with CDH had confirmation of their hypoplas-
tic lung condition at autopsy. The age of onset of NO
treatment and the duration of NO inhalation was greater in
group A than in group B, although this was not signifi-
cantly different (table 3). Starting NO concentrations were
similar in the two groups while the maximum NO concen-
trations were higher in group B. Peak metHb levels rem-
ained below 5% and were comparable in the two groups
(table 3).
Gas exchange
In the whole group a marked improvement of systemic
oxygenation during NO inhalation was observed. Pa,O2
increased from a mean baseline value of 4.4 kPa (33.2
mmHg) (95% CI 3.4–5.4 kPa (25.5–40.9 mmHg)) to 7.0
kPa (52.5 mmHg) (1.15–8.8 kPa (38.7–66.3 mmHg)) at
1 h (p=0.007), being 7.5 kPa (56.4 mmHg) (6.2–8.8 kPa
(46.8–66 mmHg)) at 24 h (p=0.02). PA-a,O2 and OI dec-
reased significantly at 1 h inhalation and this effect was
sustained at 24 h (fig. 1). When patients were retrospec-
tively divided into group A and group B, and the effect of
NO therapy compared, it was found that despite the fact
that baseline Pa,O2, PA-a,O2 and OI were not significantly
different between the two groups (table 2), there was a
distinct effect on systemic oxygenation during NO inha-
lation. In fact, patients in group A presented a rapid and
sustained response at 1, 3, 6, and 24 h of NO inhalation,
whilst none of the oxygenation parameters improved sig-
nificantly in patients in group B throughout the study
period (fig. 2).
Table 1.  –  Patient demographic and outcome data
Pt
No.
Gestat.
age
weeks
Birth
weight
kg
Diag. Surfact.
Pre-NO
HFOV
Pre-NO
ECMO/Alive
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
38
35
40
34
37
39
41
38
40
38
37
40
41
40
36
36
37
40
34
40
3.03
2.04
3.50
2.53
2.70
2.97
4.06
3.49
2.81
3.71
2.81
3.25
3.96
3.44
2.35
3.05
2.90
3.55
2.21
4.39
MAS
RDS
PIE
RDS
CDH
Sepsis
Sepsis
PPHN
MAS
CDH
CDH
Sepsis
MAS
PPHN
RDS
Sepsis
PPHN
CDH
CDH
CDH
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
Y
Y
N/Y
N/Y
Y/Y
N/Y
Y/N
N/Y
N/Y
N/Y
N/Y
Y/N
Y/N
Y/Y
Y/Y
Y/Y
N/Y
N/N
Y/Y
Y/N
N/N
Y/N
Pt: patient; Gestat.: gestational; Diag.: diagnosis; Surfact.: sur-
factant; HFOV: high-frequency oscillatory ventilation; ECMO:
extracorporeal membrane oxygenation; NO: nitric oxide; MAS:
meconium aspiration syndrome; N: No; Y: Yes; RDS: respira-
tory distress syndrome; PIE: pulmonary interstitial emphysema;
CDH: congenital diaphragmatic hernia; PPHN: persistent pul-
monary hypertension of the newborn.
Table 2.  –  Patient characteristics in the two groups
Group A
(n=8)
Group B
(n=12)
Mann-
Whitney
U-test
Gestational age
   weeks
Birth weight  kg
Gender  M/F
Inborn/outborn
Apgar score at
  1 min
Apgar score at
  5 min
Pa,O2 Pre-NO
  kPa
PA-a,O2 Pre-NO
  kPa
OI Pre-NO
38 (34–41)
2.9 (2.0–4.0)
5/3
2/6
7 (1–9)
9 (3–10)
4.5 (1.9–0.8)
82.1 (78.5–85.5)
80.5 (43.9–117)
39 (34–41)
3.3 (2.2–4.4)
9/3
5/7
7 (1–10)
7.5 (2–10)
4.4 (2.9–6.0)
83.4 (82.0–85.1)
73.7 (51–96)
p=0.64
p=0.18
p=0.56
p=0.45
p=0.65
p=0.62
p=0.70
p=0.59
p=0.70
Values are presented as median with range in parenthesis except
Pa,O2, PA-a,O2 and OI which are presented as median with 95%
confidence intervals in parenthesis. Pa,O2: arterial oxygen ten-
sion; NO: nitric oxide; PA-a,O2: alveolar-arterial pressure differ-
ence for oxygen; OI: oxygenation index. 1 kPa = 7.52 mmHg.
Table 3.  –  Characteristics during nitric oxide (NO) inha-
lation in the two groups
Group A
(n=8)
Group B
(n=12)
Mann-
Whitney
U-test
Age at NO onset  h
Length of NO
   inhalation  h
Initial NO dose ppm
Peak NO dose ppm
Peak metHb  %
45.5 (2–117)
87 (15–127)
10 (10–15)
17 (10–40)
2 (0.1–5)
19.5 (1–336)
14.5 (6–331)
12.5 (10–40)
33.5 (20–80)
1.8 (0.8–2.8)
p=0.08
p=0.10
p=0.24
p<0.01
p=0.68
Values are expressed as median with range in parenthesis.
metHb: methaemoglobin.
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Fig. 1.  –  Changes in the oxygenation index (OI) during nitric oxide
inhalation in 20 infants with severe hypoxaemic respiratory failure. An
acute and sustained improvement of OI from 1 h of treatment is obser-
ved. Values are presented as mean±SD. Baseline: n=20; 1 h: n=20; 3 h:
n=19; 6 h: n=19; 24 h: n=10. *,**: p<0.05, p<0.01 compared to baseline
using the Wilcoxon signed-rank test.
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All patients approached or fulfilled ECMO criteria:
eight patients (40%), (group A) improved with NO inha-
lation and did not require ECMO life support. Of 12
patients who deteriorated despite NO inhalation (group
B), two died before ECMO treatment and 10 underwent
ECMO. The five infants with CDH treated with ECMO
ultimately died, while the other five nonCDH infants sur-
vived. Eventually, 13 out of 20 patients (65%) were suc-
cessfully discharged home.
A variable oxygenation response was observed in the
various diagnostic categories. Among the six infants with
CDH, one showed a transient improvement of oxygena-
tion while five failed to respond to NO inhalation. All six
eventually died, five despite ECMO. Three infants with
RDS showed a good response to NO and survived. In the
remaining patients, five infants (two meconium aspirate
syndrome (MAS), two sepsis, one PPHN) improved their
oxygenation during NO and survived, while the other six
(one MAS, two sepsis, two PPHN, one pulmonary inter-
stitial emphysema (PIE)) did not show a sustained res-
ponse to NO. In the latter subgroup, one patient died and
five survived after ECMO.
Among the 15 patients evaluated by 2-D echocardio-
graphic and Doppler studies before and during NO inha-
lation, 13 showed signs of extrapulmonary right-to-left
shunting (seven in group A, six in group B). Seven pati-
ents (100%) in group A had a reversal of shunting within
1 h of NO therapy, as opposed to two (33.3%) in group B
(p=0.02). Of the two patients who had no signs of right-
to-left shunting, one died and one survived after ECMO.
Five other subjects could not be completely investigated.
During NO administration, NO2 concentration remained
<1 ppm except for two short trials at 80 ppm, when it
reached 1.8 ppm. No adverse effects related to NO inhala-
tion were observed.
Discussion
In recent years inhaled NO has gained increasing credit
as an effective and safe therapeutic option in newborns
with acute respiratory failure [3, 10–13]. In particular, two
large controlled multicentre trials have recently demon-
strated that NO therapy improves systemic oxygenation
and may reduce the need for more invasive treatments
in these patients, even if, in both studies, the mortality
rate observed by the authors was similar in the treated
and controlled groups [14, 15]. However, the reason why
some patients show a seldom or unsustained response to
NO therapy remains unclear. Furthermore, whether or not
an early oxygenation response to NO is associated with a
better outcome in these patients remains to be elucidated.
The present study has shown that inhalation of NO may
result in a marked amelioration of oxygenation in term
and near-term newborns with severe hypoxaemic respira-
tory failure and may reduce the need for ECMO.
Although the pattern of response to NO inhalation was
variable, it appeared to be correlated with outcome. In
fact, patients who showed a rapid and sustained improve-
ment of oxygenation during NO treatment were success-
fully treated with conventional mechanical ventilation.
Conversely, a poor oxygenation response within the first
hours of NO inhalation was associated with death or treat-
ment with ECMO. Reversal of a right-to-left shunting at
the ductal and/or foramen ovale level during NO was also
significantly associated with a good outcome.
The heterogeneous response to NO observed in patients
in the present study is consistent with the findings of other
studies [13, 16–18]. Such variable oxygenation responses
seem to be partially related to the underlying specific dis-
ease, although in almost all the pathological conditions
associated with PPHN, such as CDH, MAS, RDS or sep-
sis, both a good and rare response to NO have been obser-
ved in different studies [13, 16–18]. For instance, patients
with hypoplastic lungs, who may have anatomical and
functional pulmonary vascular abnormalities which pot-
entially interfere with the response to NO, were treated
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Fig. 2.  –  Changes in oxygenation parameters during nitric oxide inha-
lation in newborns who survived without extracorporeal membrane oxy-
genation (ECMO) (group A, n=8) and in newborns who survived after
ECMO or died (group B, n=12). Despite comparable baseline values in
the two groups, infants in group A showed a significant improvement in
oxygenation from 1 h of NO treatment, while infants in group B showed
no improvement in oxygenation throughout the study period. Data are
presented as mean±SD. ● : group A;    : group B; PA-a,O2: alveolar-arte-
rial pressure difference for oxygen; Pa,O2: arterial oxygen tension. *,**:
p<0.05, p<0.01 for between group comparison using the Mann-Whitney
U-test. 1 kPa = 7.52 mmHg.
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successfully with NO inhalation in some studies [12–13,
17], while hypoxaemic newborns with hypoplastic lungs
and pulmonary hypertension did not improve their oxy-
genation when inhaled NO was given prior to ECMO
[19]. In the present study, five out of six patients with
hypoplastic lungs due to CDH did not improve with NO
and all six eventually died. Furthermore, in a recent multi-
centre controlled study, inhalation of NO was not benefi-
cial in a group of 25 infants with CDH unresponsive to
aggressive conventional treatment [20]. Thus, the diagno-
sis of CDH by itself may be predictive of a more severe
prognosis. In the remaining patients, except for the sub-
group of three infants with RDS who improved with NO
and survived, the response to NO was variable in each
diagnostic category.
In a group of newborns with respiratory failure and  pul-
monary hypertension, DAY et al. [18] recently noticed that
patients with normal lung fields or focal disease had  a sig-
nificantly greater improvement of oxygenation than pati-
ents with moderate or severe diffuse lung disease. It has
been hypothesized that, different ventilatory strategies
might be involved in the variable response to NO and
in fact some authors have observed a better oxygenation
with the combined use of HFOV and NO compared with
either treatment alone [12]. By providing a more effective
alveolar recruitment [21, 22], HFOV could in fact favour
a better delivery of inhaled NO to the pulmonary micro-
circulation, with enhanced effects on pulmonary pressure
and ventilation-perfusion matching. Nevertheless, in three
patients with CDH treated with NO and HFOV no sus-
tained response to NO inhalation was observed.
In addition to the underlying specific disease, the variable
effectiveness of NO observed in hypoxaemic newborns
is probably influenced by other multiple factors, such as,
for instance, the presence of pulmonary hypertension and
right-to-left shunting. In early reports, all infants had severe
PPHN and the majority of them showed a dramatic res-
ponse to NO inhalation [10–12]. In a recent study, 11 out of
13 infants with signs of PPHN responded to NO, versus
only three out of 10 infants  without PPHN [13]. In the
present series, presence of PPHN and reversal of shunting
during NO treatment was significantly associated with a
good outcome. Yet, as suggested by a recent echocardiogra-
phic investigation [23],  in some patients oxygenation may
be enhanced during NO even without pulmonary hyperten-
sion and extra-pulmonary shunting, which may relate to the
independent effect of NO on ventilation/perfusion matching
optimization [24, 25].
In a preliminary report, TURBOW et al. [26] observed a var-
iable response time during NO treatment in 12 newborns
with PPHN, which ranged 30 min to 12 h from the NO
onset.
In the present study, all eight newborns who were suc-
cessfully treated with NO had a marked improvement of
oxygenation from 1 h of treatment, which was sustained at
6 and 24 h, versus only one out of 12 infants who eventu-
ally underwent ECMO or died. This data confirms Salt
Lake City's experience [18], where the authors found that
87% of the patients who showed acutely improved oxy-
genation during NO inhalation, lowering the OI values
<40, continued to improve and did well, while only 10%
of patients who did not respond acutely to NO showed an
improvement while receiving prolonged therapy. Conver-
sely, in a recent study performed in 25 infants with PPHN,
GOLDMAN et al. [17] observed that an early response to NO
did not guarantee either a subsequent sustained effect or
the avoidance of ECMO. In fact, 22  out of 25 patients
who showed a good initial response, 12 recovered with
NO, five survived after ECMO and five died, one despite
ECMO.
Another important issue is the differences in inclusion
and exclusion criteria chosen in different clinical trials
with inhaled NO [27]. Early studies enrolled neonates
with severe PPHN who fulfilled ECMO parameters [10–
12]. More recently, FINER et al. [13] chose an OI >20,
regardless of the presence or absence of PPHN, and the
same group adopted an OI >19 associated with a mean air-
way pressure (MAP) >14 cmH2O in a selected series of
eight premature infants [28]. In other studies, enrolment
criteria included a variety of oxygenation and haemody-
namic parameters that may have implicated different cli-
nical conditions and patient populations [16–18, 23, 26,
29]. Thus, as far as the response to NO inhalation is con-
cerned, such various experiences may be scarcely com-
parable. In the present study, although an OI >25 was  cho-
sen as the entry criterion, all but five infants had an    OI
>40 before inhalation was commenced (median OI of the
whole group was 83.7) and this was mainly due to a rapid
progression of the underlying pathological process. Inter-
estingly, initial OI was not different between patients who
responded to NO and infants who showed a scarce
response and were treated with ECMO or died. Yet, the
age at NO onset was greater in the group of patients who
did well (45 h in group A versus 19.5 h in group B), and
this may have implicated a more rapid deterioration in
the group of infants with worse outcome. Although such
difference did not reach statistical significance, this was
presumably due to the small number of subjects. Some
authors have proposed to use NO in an earlier phase of  the
disease in order to limit further iatrogenic damage to the
lung [30]. However, the risk-benefit ratio of an earlier use
of inhaled NO has not yet been clarified, and concerns
have been raised as to the potential toxicity of NO in the
neonatal [31]. In the patients in the present study no ap-
parent adverse effect possibly related to NO therapy was
observed. Yet, information on the potential toxic effects of
NO therapy are still rather limited and further controlled
studies as well as long-term follow-up evaluations are
needed.
In conclusion, the study suggests that inhaled nitric
oxide may ameliorate the systemic oxygenation in new-
borns with severe respiratory failure. Although the small
number of patients and the lack of a control group do not
allow a complete evaluation of the role of nitric oxide
therapy, it is speculated that an improvement of oxygena-
tion may be associated with a good outcome in this group
of patients. Neonates who respond to nitric oxide treat-
ment within 1–6 h will have a greater chance to be suc-
cessfully managed with inhaled nitric oxide. Conversely,
patients who show scarce or no response to nitric oxide
therapy will probably need extracorporeal membrane
oxygenation or die. The variability of clinical responses
to nitric oxide appears to be partially related to the under-
lying specific disease, and infants with hypoplastic lungs
seem to be less responsive to such therapy. Presence
and reversal of right-to-left shunting and other factors,
such as different ventilatory strategies, may also affect the
individual response to nitric oxide. A better understanding
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of the time-response patterns to nitric oxide in hypoxae-
mic newborns with different underlying conditions would
be helpful in the early recognition of nonresponder pati-
ents, addressing in a timely manner towards combined or
alternative treatments.
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